{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:46:53Z","timestamp":1792036013513,"version":"4.4.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"European Commission Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["101149577"],"award-info":[{"award-number":["101149577"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.rcsop.2026.100828","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T18:05:57Z","timestamp":1785693957000},"page":"100828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Reporting patterns of adverse drug withdrawal events using individual case safety reports in the FAERS and Eudravigilance databases"],"prefix":"10.1016","volume":"23","author":[{"given":"Zakir","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Sin\u00e9ad","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina Tabea","family":"Jungo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Reeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcsop.2026.100828_bb0005","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S0140-6736(17)31047-4","article-title":"Medication without harm: WHO\u2019S third global patient safety challenge","volume":"389","author":"Donaldson","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.rcsop.2026.100828_bb0010","article-title":"Cumulative incidence and severity of adverse drug reactions and associated patient characteristics in older community-dwelling adults attending general practice \u2013 a six year prospective cohort study","author":"Doherty","year":"2022","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.rcsop.2026.100828_bb0015","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare"},{"key":"10.1016\/j.rcsop.2026.100828_bb0020","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Therapeutic advances in drug safety"},{"key":"10.1016\/j.rcsop.2026.100828_bb0025","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s40264-022-01246-4","article-title":"Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database","volume":"45","author":"Gastaldon","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.rcsop.2026.100828_bb0030","article-title":"Evaluation of health care professionals\u2019 knowledge, attitudes, practices and barriers to pharmacovigilance and adverse drug reaction reporting: A cross-sectional multicentral study","volume":"18","author":"Khan","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.rcsop.2026.100828_bb0035","author":"WHO"},{"key":"10.1016\/j.rcsop.2026.100828_bb0040","author":"FDA"},{"key":"10.1016\/j.rcsop.2026.100828_bb0045","author":"EMA"},{"key":"10.1016\/j.rcsop.2026.100828_bb0050","doi-asserted-by":"crossref","first-page":"1385651","DOI":"10.3389\/fphar.2024.1385651","article-title":"Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.rcsop.2026.100828_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ph15050565","article-title":"A focus on abuse\/misuse and withdrawal issues with selective serotonin reuptake inhibitors (SSRIs): analysis of both the European EMA and the US FAERS pharmacovigilance databases","volume":"15","author":"Chiappini","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.rcsop.2026.100828_bb0060","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.rcsop.2026.100828_bb0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jgs.19241","article-title":"Assessing causality in deprescribing studies: A focus on adverse drug events and adverse drug withdrawal events","volume":"73","author":"Li","year":"2025","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.rcsop.2026.100828_bb0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40266-023-01080-y","article-title":"Evaluating the safety of an educational Deprescribing intervention: lessons from the optimize trial","volume":"41","author":"Boyd","year":"2024","journal-title":"Drugs Aging"},{"key":"10.1016\/j.rcsop.2026.100828_bb0075","first-page":"1","article-title":"Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders","author":"Wis\u0142owska-Stanek","year":"2024","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.rcsop.2026.100828_bb0080","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000370338","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review","volume":"84","author":"Fava","year":"2015","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.rcsop.2026.100828_bb0085","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1111\/jgs.17883","article-title":"Deprescribing trials: A focus on adverse drug withdrawal events","volume":"70","author":"Hanlon","year":"2022","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.rcsop.2026.100828_bb0090","article-title":"Criteria to report adverse drug withdrawal events in clinical trials: A systematic review","author":"Lee","year":"2025","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.rcsop.2026.100828_bb0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1370\/afm.2336","article-title":"Managing antidepressant discontinuation: A systematic review","volume":"17","author":"Maund","year":"2019","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.rcsop.2026.100828_bb0100","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/gerona\/gls001","article-title":"Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans","volume":"67","author":"Marcum","year":"2012","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.rcsop.2026.100828_bb0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.17161\/kjm.vol1414653","article-title":"A retrospective review of morbidity and mortality associated with acute benzodiazepine withdrawal at a Midwestern Academic Medical Center","volume":"14","author":"Thornton","year":"2021","journal-title":"Kans J Med"},{"key":"10.1016\/j.rcsop.2026.100828_bb0110","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ejim.2013.05.014","article-title":"Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself","volume":"24","author":"Dinsen","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rcsop.2026.100828_bb0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/PAF.0b013e3181875aa0","article-title":"A fatal case of benzodiazepine withdrawal","volume":"30","author":"Lann","year":"2009","journal-title":"Am J Forensic Med Pathol"},{"key":"10.1016\/j.rcsop.2026.100828_bb0120","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1532-5415.2008.01916.x","article-title":"Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process","volume":"56","author":"Bain","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.rcsop.2026.100828_bb0125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jad.2021.10.041","article-title":"Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: a real-world study using the WHO pharmacovigilance database","volume":"297","author":"Quilichini","year":"2022","journal-title":"J Affect Disord"},{"key":"10.1016\/j.rcsop.2026.100828_bb0130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4140\/TCP.n.2021.136","article-title":"Avoiding adverse drug withdrawal events when stopping unnecessary medications according to the STOPPFrail criteria","volume":"36","author":"Hanlon","year":"2021","journal-title":"The Senior care pharmacist"},{"key":"10.1016\/j.rcsop.2026.100828_bb0135","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2215-0366(19)30331-1","article-title":"Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England","volume":"6","author":"Marsden","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.rcsop.2026.100828_bb0140","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/bcp.12732","article-title":"A systematic review of the emerging definition of \u2018deprescribing\u2019 with network analysis: implications for future research and clinical practice","volume":"80","author":"Reeve","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rcsop.2026.100828_bb0145","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.sapharm.2018.08.014","article-title":"Deprescribing recommendations: An essential consideration for clinical guideline developers","volume":"15","author":"Moriarty","year":"2019","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.rcsop.2026.100828_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10020105","article-title":"Focus on clozapine withdrawal-and misuse-related cases as reported to the European medicines agency (EMA) pharmacovigilance database","volume":"10","author":"Chiappini","year":"2020","journal-title":"Brain Sci"},{"key":"10.1016\/j.rcsop.2026.100828_bb0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40801-021-00240-z","article-title":"Diclofenac and the risk of rhabdomyolysis: analysis of publications and the WHO global pharmacovigilance database","volume":"8","author":"Russom","year":"2021","journal-title":"Drugs-Real World Outcomes"},{"key":"10.1016\/j.rcsop.2026.100828_bb0160","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01855-2017","article-title":"Baclofen and sleep apnoea syndrome: analysis of VigiBase, the WHO pharmacovigilance database","volume":"51","author":"Revol","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rcsop.2026.100828_bb0165","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00213-024-06554-4","article-title":"Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022","volume":"241","author":"Storck","year":"2024","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.rcsop.2026.100828_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ph15050565","article-title":"A focus on abuse\/misuse and withdrawal issues with selective serotonin reuptake inhibitors (SSRIs): analysis of both the European EMA and the US FAERS pharmacovigilance databases","volume":"15","author":"Chiappini","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.rcsop.2026.100828_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003862","article-title":"GP-delivered medication review of polypharmacy, deprescribing, and patient priorities in older people with multimorbidity in Irish primary care (SPPiRE study): A cluster randomised controlled trial","volume":"19","author":"McCarthy","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.rcsop.2026.100828_bb0180","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.sapharm.2018.08.013","article-title":"Deprescribing: future directions for research","volume":"15","author":"Thompson","year":"2019","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.rcsop.2026.100828_bb0185","series-title":"Reporting patterns and disproportionality analysis of adverse drug withdrawal events using individual case safety reports in US and European databases: a study protocol","author":"Khan","year":"2025"},{"key":"10.1016\/j.rcsop.2026.100828_bb0190","author":"FDA"},{"key":"10.1016\/j.rcsop.2026.100828_bb0195","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1038\/s41598-025-87421-w","article-title":"Disproportionality analysis of Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system","volume":"15","author":"Lee","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.rcsop.2026.100828_bb0200","author":"MedDRA"},{"key":"10.1016\/j.rcsop.2026.100828_bb0205","author":"EMA"},{"key":"10.1016\/j.rcsop.2026.100828_bb0210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40360-024-00782-2","article-title":"Drug-induced liver injury associated with atypical generation antipsychotics from the FDA adverse event reporting system (FAERS)","volume":"25","author":"He","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.rcsop.2026.100828_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1288362","article-title":"Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)","volume":"15","author":"Bao","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.rcsop.2026.100828_bb0220","author":"EMA"},{"key":"10.1016\/j.rcsop.2026.100828_bb0225","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","article-title":"EudraVigilance medicines safety database: publicly accessible data for research and public health protection","volume":"41","author":"Postigo","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.rcsop.2026.100828_bb0230","doi-asserted-by":"crossref","unstructured":"Khan, Z. & Moriarty, F. Data and materials for \"Reporting patterns of adverse drug withdrawal events using individual case safety reports in United States and European databases\" (Version v1.0). Zenodo. Accessed July 20, 2026 https:\/\/zenodo.org\/records\/18155023.","DOI":"10.64898\/2026.06.15.26355690"},{"key":"10.1016\/j.rcsop.2026.100828_bb0235","author":"RxNorm"},{"key":"10.1016\/j.rcsop.2026.100828_bb0240","author":"FDA"},{"key":"10.1016\/j.rcsop.2026.100828_bb0245","author":"WHO"},{"key":"10.1016\/j.rcsop.2026.100828_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.10.001","article-title":"Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century","volume":"17","author":"Watson","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.rcsop.2026.100828_bb0255","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.rcsop.2026.100828_bb0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40360-020-0392-9","article-title":"Adverse drug reactions in older adults: a retrospective comparative analysis of spontaneous reports to the German Federal Institute for Drugs and Medical Devices","volume":"21","author":"Dubrall","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.rcsop.2026.100828_bb0265","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.4155","article-title":"Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden","volume":"26","author":"Holm","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rcsop.2026.100828_bb0270","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1186\/s12877-024-05515-y","article-title":"Adverse drug reactions and its associated factors among geriatric hospitalized patients at selected comprehensive specialized hospitals of the Amhara region, Ethiopia: a multicenter prospective cohort study","volume":"24","author":"Dagnew","year":"2024","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.rcsop.2026.100828_bb0275","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/picr.PICR_64_17","article-title":"An analysis of adverse drug reactions in extremes of age group at tertiary care teaching hospital","volume":"9","author":"Amin","year":"2018","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.rcsop.2026.100828_bb0280","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/0115748863276456231016062628","article-title":"An awareness of pharmacovigilance among healthcare professionals due to an underreporting of adverse drug reactions issue: A systematic review of the current state, obstacles, and strategy","volume":"19","author":"Putri","year":"2024","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.rcsop.2026.100828_bb0285","doi-asserted-by":"crossref","DOI":"10.1177\/20503121241249908","article-title":"Exploring pharmacovigilance practices and knowledge among healthcare professionals: A cross-sectional multicenter study","volume":"12","author":"Hayek","year":"2024","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.rcsop.2026.100828_bb0290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions\u202f: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.rcsop.2026.100828_bb0295","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40264-023-01302-7","article-title":"Factors associated with underreporting of adverse drug reactions by health care professionals: A systematic review update","volume":"46","author":"Garc\u00eda-Abeijon","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.rcsop.2026.100828_bb0300","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jsps.2022.04.006","article-title":"Spontaneous adverse drug reaction reporting by community pharmacists: preparedness and barriers","volume":"30","author":"Bahlol","year":"2022","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.rcsop.2026.100828_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253588","article-title":"Pharmacist-led educational interventions provided to healthcare providers to reduce medication errors: A systematic review and meta-analysis","volume":"16","author":"Jaam","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.rcsop.2026.100828_bb0310","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jsps.2016.12.004","article-title":"Knowledge, attitude and practices of pharmacovigilance and adverse drug reaction reporting among pharmacists working in secondary and tertiary governmental hospitals in Kuwait","volume":"25","author":"Alsaleh","year":"2017","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.rcsop.2026.100828_bb0315","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jsps.2014.07.001","article-title":"Pharmacist's knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process","volume":"23","author":"Suyagh","year":"2015","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.rcsop.2026.100828_bb0320","doi-asserted-by":"crossref","first-page":"569","DOI":"10.26719\/2018.24.6.569","article-title":"Syrian pharmacovigilance system: a survey of pharmacists' knowledge, attitudes and practices","volume":"24","author":"Bahnassi","year":"2018","journal-title":"East Mediterr Health J"},{"key":"10.1016\/j.rcsop.2026.100828_bb0325","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.sapharm.2004.12.009","article-title":"The role of hospital and community pharmacists in pharmacovigilance","volume":"1","author":"van Grootheest","year":"2005","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.rcsop.2026.100828_bb0330","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s11096-022-01449-w","article-title":"Implementation of pharmacist-led deprescribing in collaborative primary care settings","volume":"44","author":"Trenaman","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.rcsop.2026.100828_bb0335","author":"FDA"},{"key":"10.1016\/j.rcsop.2026.100828_bb0340","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0163-8343(94)90051-5","article-title":"Introducing MEDWatch: A new approach to reporting medication and device adverse effects and product problems","volume":"16","author":"Kessler","year":"1994","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.rcsop.2026.100828_bb0345","doi-asserted-by":"crossref","DOI":"10.1080\/20523211.2024.2417399","article-title":"Pharmacovigilance: the evolution of drug safety monitoring","volume":"17","author":"Khan","year":"2024","journal-title":"Journal of Pharmaceutical Policy and Practice"},{"key":"10.1016\/j.rcsop.2026.100828_bb0350","author":"EMA"},{"key":"10.1016\/j.rcsop.2026.100828_bb0355","author":"EMA"},{"key":"10.1016\/j.rcsop.2026.100828_bb0360","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis","volume":"71","author":"Ciccarone","year":"2019","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.rcsop.2026.100828_bb0365","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.rcsop.2026.100828_bb0370","doi-asserted-by":"crossref","first-page":"18817","DOI":"10.1038\/s41598-023-46275-w","article-title":"Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events","volume":"13","author":"Montes-Grajales","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.rcsop.2026.100828_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1145645","article-title":"A comparative analysis on serious adverse events reported for COVID-19 vaccines in adolescents and young adults","volume":"11","author":"Cappelletti-Montano","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.rcsop.2026.100828_bb0380","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/pds.704","article-title":"Reports of withdrawal syndrome with the use of SSRIs: a case\/non-case study in the French pharmacovigilance database","volume":"11","author":"Trenque","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rcsop.2026.100828_bb0385","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clindermatol.2009.06.019","article-title":"The challenge of drug-rechallenge: facts and controversies","volume":"28","author":"Davidovici","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.rcsop.2026.100828_bb0390","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.70356","article-title":"Strengthening pharmacovigilance reporting for withdrawal reactions to support Deprescribing","author":"Khan","year":"2026","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.rcsop.2026.100828_bb0395","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s11096-018-0694-9","article-title":"Comparison of different methods for causality assessment of adverse drug reactions","volume":"40","author":"Behera","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.rcsop.2026.100828_bb0400","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40264-017-0509-2","article-title":"Causality assessment in pharmacovigilance: still a challenge","volume":"40","author":"Ralph Edwards","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.rcsop.2026.100828_bb0405","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/jcpt.13114","article-title":"Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management","volume":"45","author":"Pergolizzi","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.rcsop.2026.100828_bb0410","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/ajad.12862","article-title":"Review article: effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment","volume":"28","author":"Kosten","year":"2019","journal-title":"Am J Addict"},{"key":"10.1016\/j.rcsop.2026.100828_bb0415","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","volume":"3","author":"Baandrup","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rcsop.2026.100828_bb0420","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40360-025-00869-4","article-title":"A pharmacovigilance study of olanzapine\/samidorphan based on FDA adverse event reporting system (FAERS)","volume":"26","author":"He","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.rcsop.2026.100828_bb0425","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40263-013-0079-5","article-title":"Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations","volume":"27","author":"Cerovecki","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.rcsop.2026.100828_bb0430","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.rcsop.2026.100828_bb0435","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s40264-016-0463-4","article-title":"Completeness of spontaneous adverse drug reaction reports sent by general practitioners to a regional pharmacovigilance Centre: A descriptive study","volume":"39","author":"Durrieu","year":"2016","journal-title":"Drug Saf"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276626001265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276626001265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:12:02Z","timestamp":1792033922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276626001265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":87,"alternative-id":["S2667276626001265"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2026.100828","relation":{},"ISSN":["2667-2766"],"issn-type":[{"value":"2667-2766","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reporting patterns of adverse drug withdrawal events using individual case safety reports in the FAERS and Eudravigilance databases","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2026.100828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100828"}}